Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Subscribe To Our Newsletter & Stay Updated
